查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1716781

细胞和基因治疗製造服务市场按服务类型、技术类型、治疗领域、应用和最终用户划分——2025 年至 2030 年全球预测

Cell & Gene Therapy Manufacturing Services Market by Service Type, Technology Type, Therapeutic Area, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计细胞和基因治疗製造服务市场在 2023 年的价值将达到 173.3 亿美元，到 2024 年将以 15.81% 的复合年增长率增长至 199.8 亿美元，到 2030 年将达到 484.4 亿美元。

主要市场统计数据
基准年2023年 173.3亿美元
预计年份：2024年 199.8亿美元
预测年份 2030 484.4亿美元
复合年增长率（%） 15.81%

在当今快速发展的环境中，细胞和基因治疗製造业处于改变现代医学的前沿。在前所未有的科学突破和解决复杂疾病的迫切需求的推动下，这个市场具有动态创新和转型潜力的特征。该部门的製造服务旨在确保新型治疗方法以安全、高效和可扩展的方式从研究转向临床应用。随着技术的不断进步和法规环境的加强，该领域的公司不断改进其方法，以满足全球对优质治疗解决方案日益增长的需求。

我们的製造商投资最先进的设备并实施最尖端科技，以在整个生产过程中保持卓越的品质。随着公共和私营部门更加重视个人化医疗，对细胞和基因治疗技术的投资达到了历史最高水准。这份全面的概述探讨了最重要的行业趋势，并提供了深入的见解以帮助进行策略规划，鼓励相关人员适应并在竞争激烈的市场环境中取得成功。

该内容结合了广泛的研究和先进的分析方法，提供了有关製造能力和市场趋势的重要背景和清晰度。学术界、委外研发机构和大型製药企业之间的合作凸显了寻求创新解决方案的紧迫性，它们都为产业成长和发展的强大生态系统做出了贡献。在这种背景下，製造服务对于向世界各地的患者提供创新的临床解决方案至关重要。

改变细胞和基因治疗製造服务市场

细胞和基因治疗製造业正在经历一场变革性转变，这场转变正在重塑产业范式并推动快速进步。在过去的几年中，治疗方法开发、製造和分销的根本性质已经发生了彻底的改变，从传统的生技药品製造转向高度专业化的治疗平台。公司正在利用创新技术、先进的自动化和数位整合来简化製造流程、确保一致性并提高整体安全性。随着这些开创性疗法的出现，监管审查也越来越严格，对数据完整性、可重复性和品管的要求也越来越高，这也推动了这种转变。

流程开发的持续创新正在突破可扩展性和效率的界限。製造商目前面临的挑战是同时满足小批量临床生产和大规模商业製造要求。随着技术整合变得越来越主流，流程变得越来越适应量身定制的治疗方法，体现了个人化护理所需的灵活性。此外，生物技术公司、学术研究机构和监管机构之间的策略联盟与合作极大地促进了技术转移和知识共用，从而产生了更灵活的製造方法。

从引入高性能筛检方法到采用强大的品管框架，该领域的技术力正在迅速扩展。随着干细胞研究和基因编辑方法的进步，对个人化研究的需求不断增加，该行业正在走向更有效率、可靠和可扩展的製造模式。这些转型转变凸显了该产业向先进创新网路的演变，其中卓越的营运对于维持成长和改善全球患者的治疗效果至关重要。

差异化市场分析的关键细分洞察

透过考虑市场区隔的各个方面，可以理解细胞和基因治疗製造服务的复杂性。服务类型是分析的主要驱动力，因为市场研究涉及分析和品管服务、细胞库服务、咨询服务、填充和完成服务、GMP 製造服务、流程开发服务、监管支援服务、供应链和物流服务、技术转移服务和载体製造服务等类别。每项服务都发挥着至关重要的作用，确保治疗达到最高标准，同时保持高效的生产计划。

除了基于服务的细分之外，技术细微差别对于理解市场成长动态也至关重要。经过深入分析，技术格局分为基因编辑技术和载体技术。在基因编辑方面，CRISPR/Cas9、转录活化因子样效应核酸酶和锌指核酸酶等平台可以精确修改基因组结构，有助于改善治疗效果。载体技术进一步分为非病毒平台和病毒平台。非病毒载体系统包括阳离子脂质、几丁聚醣基载体、树状聚合物、无机奈米颗粒、脂质体、裸露DNA/RNA、肽基载体和聚合物载体，因其安全性和可扩展性而受到高度重视。相反，病毒载体则被视为腺结合病毒载体、腺病毒载体、单纯疱疹病毒载体和逆转录病毒载体，每种载体在转导效率和靶向递送方面都具有独特的优势。

透过在心血管疾病、感染疾病、一次性疾病和肿瘤学的背景下分析市场，治疗细分增加了另一层洞察力。心血管疾病中的冠状动脉疾病和心臟衰竭，感染疾病中的乙肝和爱滋病毒，以及一次性疾病中的囊肿纤维化、血友病和镰状细胞性贫血等特定疾病，体现了对小众疾病领域的深入关注。本文也深入回顾了肿瘤学，并专注于骨髓恶性肿瘤和固态肿瘤。根据应用和治疗领域进行细分，临床製造与商业製造有所区别，每种製造都需要自己的营运策略和品质保证通讯协定。

透过将市场细分为受託研究机构、医院诊所、製药和生物技术公司、研究机构和学术机构等，最终用户分析进一步丰富了分析框架。这种细分框架使相关人员和决策者能够细緻地了解每个细分市场的独特行为、需求和成长前景，从而能够更有针对性地制定策略并有效地配置资源。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 慢性病和遗传性疾病盛行率上升
      • 增加政府对先进治疗方法研发的经费与津贴
    • 限制因素
      • 细胞和基因治疗製造相关的高营运成本
    • 机会
      • CRISPR 技术的广泛应用为基因工程服务创造了新的成长轨迹
      • 生物加工设备的技术进步为高效生产过程铺平了道路
    • 任务
      • 细胞和基因治疗製造中的品管和污染问题
  • 市场区隔分析
    • 服务类型：需要提供安全储存和存取各种细胞株的细胞银行服务
    • 技术类型：病毒载体增殖，实现高转染效率和稳定的基因表现
    • 治疗领域：细胞和基因治疗在肿瘤学中治疗造血系统恶性肿瘤和固态肿瘤的意义
    • 用途：使用临床製造进行临床前和临床测试
    • 最终用户：製药和生物技术公司越来越多地采用该技术来开发和商业化创新治疗方法
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

6. 细胞和基因治疗製造服务市场（按服务类型）

  • 介绍
  • 分析和品管服务
  • 细胞银行服务
  • 咨询服务
  • 灌装和精加工服务
  • GMP生产服务
  • 製程开发服务
  • 监管支援服务
  • 供应炼和物流服务
  • 技术转移服务
  • 向量创建服务

7. 细胞和基因治疗製造服务市场（依技术类型）

  • 介绍
  • 基因编辑
    • CRISPR/Cas9
    • 转录活化因子样效应核酸酶
    • 锌指核酸酶
  • 向量
    • 非病毒载体
      • 阳离子脂质
      • 几丁聚醣载体
      • 树状聚合物
      • 无机奈米粒子
      • 脂质体
      • 裸露的DNA/RNA
      • 基于胜肽的载体
      • 聚合物载体
    • 病毒载体
      • 腺结合病毒（AAV）载体
      • 腺病毒载体
      • 单纯疱疹病毒（HSV）载体
      • 逆转录病毒载体

第八章细胞和基因治疗製造服务市场（按治疗领域）

  • 介绍
  • 心血管疾病
    • 冠状动脉疾病
    • 心臟衰竭
  • 感染疾病
    • B型肝炎
    • HIV
  • 单基因疾病
    • 囊肿纤维化
    • 血友病
    • 镰状细胞性贫血
  • 肿瘤学
    • 造血系统恶性肿瘤
    • 固态肿瘤

第九章细胞和基因治疗製造服务市场（按应用）

  • 介绍
  • 临床製造
  • 商业製造

第 10 章细胞和基因治疗製造服务市场（按最终用户）

  • 介绍
  • 合约研究组织
  • 医院和诊所
  • 製药和生物技术公司
  • 研究和学术机构

11.美洲细胞与基因治疗製造服务市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太细胞与基因治疗製造服务市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲细胞和基因治疗製造服务市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Advanced BioScience Laboratories, Inc. by Institut Merieux
  • AGC Biologics
  • AmplifyBio
  • Bio-Techne Corporation
  • CH Boehringer Sohn AG & Co. KG
  • Catalent, Inc.
  • Cell Therapies Pty Ltd.
  • Cell-Easy
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • eXmoor Pharma Concepts Limited
  • FUJIFILM Diosynth BIoTechnologies
  • Genezen Laboratories, Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi BIoTec BV & Co. KG
  • Minaris Regenerative Medicine GmbH by Resonac Corporation
  • Nikon Corporation
  • Novartis AG
  • Oxford Biomedica PLC
  • ProPharma Group Holdings, LLC
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • SGS SA
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uBriGene Biosciences Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-BB6269D1414B

The Cell & Gene Therapy Manufacturing Services Market was valued at USD 17.33 billion in 2023 and is projected to grow to USD 19.98 billion in 2024, with a CAGR of 15.81%, reaching USD 48.44 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 17.33 billion
Estimated Year [2024] USD 19.98 billion
Forecast Year [2030] USD 48.44 billion
CAGR (%) 15.81%

In today's rapidly evolving landscape, the cell and gene therapy manufacturing sector is at the forefront of revolutionizing modern medicine. Driven by unprecedented scientific breakthroughs and an urgent need to address complex diseases, this market is characterized by its dynamic innovation and transformative potential. The manufacturing services in this sector are designed to ensure that emerging therapies progress from research to clinical application in safe, efficient, and scalable ways. With constant technological advancements and a robust regulatory environment, companies in this field are continually refining their methods to meet increasing global demand for high-quality therapeutic solutions.

Manufacturers are investing in state-of-the-art facilities and integrating cutting-edge technology to maintain superior quality throughout the production process. As both the private and public sectors place greater emphasis on personalized healthcare, investment in cell and gene therapy technology has never been higher. This comprehensive summary explores the most significant industry trends and provides detailed insights that are instrumental for strategic planning, urging stakeholders to adapt and thrive in a competitive market landscape.

By combining extensive research with advanced analytical methodologies, the content here offers essential context, background, and clarity regarding manufacturing capabilities and market trends. The urgency for innovative solutions is underscored by collaborations between academia, contract research organizations, and large pharmaceutical companies, each contributing to a robust ecosystem of industry growth and development. In this context, the role of manufacturing services is pivotal to the delivery of transformative clinical solutions to patients around the world.

Transformative Shifts in the Cell & Gene Therapy Manufacturing Landscape

The cell and gene therapy manufacturing sector is experiencing transformative shifts that are reshaping the industry paradigm and driving rapid advancements. Over the past several years, the fundamental nature of how therapies are developed, produced, and distributed has undergone a complete overhaul, marking a transition from traditional biologics manufacturing to highly specialized therapeutic platforms. Companies are harnessing innovative technologies, advanced automation, and digital integration to streamline production processes, ensure consistency, and improve overall safety. This transformation is also spurred by the heightened regulatory scrutiny that now accompanies these pioneering treatments, with regulators demanding higher levels of data integrity, reproducibility, and quality control.

Continuous innovation in process development is pushing the boundaries of scalability and efficiency. Manufacturers are now challenged to accommodate small-batch clinical production alongside large-scale commercial manufacturing requirements. As technological integration becomes mainstream, processes are increasingly becoming adaptable to a tailored therapeutic approach, embodying flexibility that is necessary for personalized treatments. Additionally, strategic partnerships and collaborations between biotech companies, academic research institutions, and regulatory bodies have significantly expedited technology transfer and knowledge sharing, which in turn have led to more agile production practices.

From the incorporation of high-throughput screening methods to the adoption of robust quality control frameworks, the sector's technological capability is expanding rapidly. As the demand for personalized therapies grows in tandem with advancements in stem cell research and gene editing methodologies, the industry is charting a course towards more efficient, reliable, and scalable manufacturing models. These transformative shifts underscore the sector's evolution into a sophisticated network of innovation where operational excellence is critical for sustaining growth and improving patient outcomes worldwide.

Key Segmentation Insights for a Differentiated Market Analysis

The intricacies of cell and gene therapy manufacturing services can be understood by examining the various dimensions through which the market has been segmented. Service types are a primary driver for analysis, as the market is examined across categories such as analytical and quality control services, cell banking services, consulting services, fill and finish services, GMP manufacturing services, process development services, regulatory support services, supply chain and logistics services, technology transfer services, and vector production services. Each of these service offerings plays a crucial role in ensuring that therapies are produced to the highest possible standards while maintaining efficient production timelines.

In addition to service-based segmentation, technological nuances are integral to deciphering the market's growth dynamics. A thorough analysis divides the technological landscape into gene editing and vector technologies. Within gene editing, platforms such as CRISPR/Cas9, transcription activator-like effector nucleases, and zinc finger nucleases are instrumental in allowing precise modifications in the genomic structure, thereby enhancing therapy outcomes. Vector technologies are further dissected into non-viral and viral platforms. Non-viral vector systems, which include cationic lipids, chitosan-based vectors, dendrimers, inorganic nanoparticles, liposomes, naked DNA/RNA, peptide-based vectors, and polymeric vectors, are celebrated for their safety profile and scalability. Conversely, viral vectors are examined through the lens of adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors, each offering unique advantages in terms of transduction efficiency and targeted delivery.

Therapeutic area segmentation provides another layer of insight, with the market being analyzed in the contexts of cardiovascular diseases, infectious diseases, monogenic disorders, and oncology. Specific conditions such as coronary artery disease and heart failure within cardiovascular diseases, hepatitis B and HIV within infectious diseases, and cystic fibrosis, hemophilia, and sickle cell anemia among monogenic disorders illustrate the detailed focus on niche disease areas. Oncology is also meticulously reviewed, with attention distributed between hematological malignancies and solid tumors. Beyond therapeutic divisions, a further segmentation based on application distinguishes between clinical manufacturing and commercial manufacturing, each necessitating its own set of operational strategies and quality assurance protocols.

Profiling based on end-user further enriches the analytical framework, as the market is segmented across contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes and academic institutions. This segmentation framework empowers stakeholders and decision-makers by providing a nuanced understanding of each market segment's unique behaviors, needs, and growth prospects, thereby enabling more targeted strategy formulations and effective resource allocation.

Based on Service Type, market is studied across Analytical & Quality Control Services, Cell Banking Services, Consulting Services, Fill & Finish Services, GMP Manufacturing Services, Process Development Services, Regulatory Support Services, Supply Chain & Logistics Services, Technology Transfer Services, and Vector Production Services.

Based on Technology Type, market is studied across Gene Editing and Vectors. The Gene Editing is further studied across CRISPR/Cas9, Transcription Activator-Like Effector Nucleases, and Zinc Finger Nucleases. The Vectors is further studied across Non-Viral Vectors and Viral Vectors. The Non-Viral Vectors is further studied across Cationic Lipids, Chitosan-Based Vectors, Dendrimers, Inorganic Nanoparticles, Liposomes, Naked DNA/RNA, Peptide-Based Vectors, and Polymeric Vectors. The Viral Vectors is further studied across Adeno-Associated Virus (AAV) Vectors, Adenovirus Vectors, Herpes Simplex Virus (HSV) Vectors, and Retrovirus Vectors.

Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Infectious Diseases, Monogenic Disorders, and Oncology. The Cardiovascular Diseases is further studied across Coronary Artery Disease and Heart Failure. The Infectious Diseases is further studied across Hepatitis B and HIV. The Monogenic Disorders is further studied across Cystic Fibrosis, Hemophilia, and Sickle Cell Anemia. The Oncology is further studied across Hematological Malignancies and Solid Tumors.

Based on Application, market is studied across Clinical Manufacturing and Commercial Manufacturing.

Based on End-User, market is studied across Contract Research Organizations, Hospitals & Clinics, Pharmaceutical & Biotech Companies, and Research Institutes & Academic Institutions.

Regional Insights: Assessing the Global Market Landscape

Analyzing the market through a global lens reveals distinctive trends and competitive dynamics across various regions. In the Americas, advanced infrastructure, a conducive regulatory environment, and a robust network of clinical research institutions are creating a fertile ground for the adoption and scaling of cell and gene therapy technologies. Market participants in this region benefit from a strong focus on innovation supported by well-funded academic and private research initiatives, which continuously drive breakthrough developments.

The combined territory of Europe, the Middle East, and Africa has emerged as a vital hub for both innovation and regulatory prowess. In Europe, rigorous standards enforced by regulatory bodies have led to the development of high-quality manufacturing practices, ensuring that therapies adhere to the most stringent safety protocols. Meanwhile, emerging markets within the Middle East and Africa are progressively investing in state-of-the-art manufacturing facilities and seeking collaborations with global industry leaders to uplift their capabilities and expertise in cell and gene therapy production.

Asia-Pacific has become a powerhouse in the global pharmaceutical landscape, largely due to its rapid economic growth, increased investment in technology, and an accelerating pace of regulatory harmonization. Countries in this region are strategically focused on enhancing their capabilities in both clinical and commercial manufacturing, which is attracting substantial foreign investments and forging strategic alliances with international manufacturers. Such regional insights illustrate that while each region exhibits its own distinct set of opportunities and challenges, the overarching trend is one of collaborative growth and robust market expansion worldwide.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Industry Leaders: A Deep Dive into Key Company Performance Drivers

A critical component of uncovering emerging trends in the cell and gene therapy manufacturing space involves a close examination of the actions and performance of key companies. Research and development efforts by entities such as Advanced BioScience Laboratories, Inc. by Institut Merieux and AGC Biologics have set the benchmark for quality and innovation across the industry. Companies including AmplifyBio, Bio-Techne Corporation, and C.H. Boehringer Sohn AG & Co. KG have further contributed to the progression of manufacturing technologies through advanced analytical capabilities and seamless integration of quality control systems.

Other market leaders such as Catalent, Inc. and Cell Therapies Pty Ltd. are not only enhancing process optimization but are also pioneering breakthroughs in cell banking and process development strategies. Firms like Cell-Easy and Charles River Laboratories International, Inc. have become synonymous with reliable supply chain management that supports wide-ranging production demands. The strategic insights from heavyweight players such as Danaher Corporation, eXmoor Pharma Concepts Limited, FUJIFILM Diosynth Biotechnologies, and Genezen Laboratories, Inc. exemplify the drive towards harnessing next-generation manufacturing technologies to ensure sustained growth.

The presence of major corporations like Laboratory Corporation of America Holdings, Lonza Group AG, Merck KGaA, and Miltenyi Biotec B.V. & Co. KG further reinforces industry confidence by demonstrating long-standing expertise in optimizing and scaling manufacturing processes. In addition, influential market players such as Minaris Regenerative Medicine GmbH by Resonac Corporation, Nikon Corporation, Novartis AG, Oxford Biomedica PLC, and ProPharma Group Holdings, LLC have seamlessly integrated innovative systems that optimize quality, compliance, and production throughput. Strategic insights offered by companies like Recipharm AB, Samsung Biologics Co., Ltd., SGS S.A., STEMCELL Technologies Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., uBriGene Biosciences Inc., and WuXi AppTec Co., Ltd. highlight the importance of effort in aligning technological advancements with operational efficiency. Collectively, these key companies set a robust foundation for the sector by championing rigorous quality standards and embracing innovation at every stage of the product lifecycle.

The report delves into recent significant developments in the Cell & Gene Therapy Manufacturing Services Market, highlighting leading vendors and their innovative profiles. These include Advanced BioScience Laboratories, Inc. by Institut Merieux, AGC Biologics, AmplifyBio, Bio-Techne Corporation, C.H. Boehringer Sohn AG & Co. KG, Catalent, Inc., Cell Therapies Pty Ltd., Cell-Easy, Charles River Laboratories International, Inc., Danaher Corporation, eXmoor Pharma Concepts Limited, FUJIFILM Diosynth Biotechnologies, Genezen Laboratories, Inc., Laboratory Corporation of America Holdings, Lonza Group AG, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Minaris Regenerative Medicine GmbH by Resonac Corporation, Nikon Corporation, Novartis AG, Oxford Biomedica PLC, ProPharma Group Holdings, LLC, Recipharm AB, Samsung Biologics Co., Ltd., SGS S.A., STEMCELL Technologies Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., uBriGene Biosciences Inc., and WuXi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are urged to leverage emerging trends by embracing collaborative innovation and agile manufacturing protocols to remain competitive in an increasingly complex market. It is recommended to invest in advanced technological platforms for process optimization that not only reduce production time but also enhance product quality and consistency. Leaders should prioritize the adoption of digitalization solutions, including data analytics and automation, to streamline validation processes and improve overall operational efficiency. By integrating these systems, companies can foresee challenges in real-time and achieve a more responsive manufacturing ecosystem.

Furthermore, fostering robust partnerships with regulatory bodies enables a proactive approach in aligning production standards with evolving global requirements. This can be achieved by developing comprehensive training programs that ensure staff remains adept at utilizing cutting-edge technology while adhering to stringent quality control measures. A renewed focus on technology transfer and strategic collaborations across cross-functional teams will also help in bridging the gap between clinical research and commercial production capabilities. Furthermore, diversifying service portfolios by incorporating end-to-end manufacturing solutions can help cater to the varying needs of both clinical and commercial manufacturing segments.

Industry leaders must also consider environmental sustainability as an integral part of manufacturing excellence. Investing in green technologies and reducing resource wastage during production not only contributes to corporate responsibility but also enhances long-term operational viability. In conclusion, a multifaceted approach that intertwines process innovation, regulatory engagement, staff training, and sustainability investments will serve as the cornerstone for achieving both immediate and long-term success in the cell and gene therapy manufacturing domain.

Conclusion: Charting the Path Forward in Cell & Gene Therapy Manufacturing

In summary, the evolution of cell and gene therapy manufacturing services is marked by significant shifts that are transforming how therapies are developed and delivered. The integration of advanced technologies with rigorous quality control, the strategic segmentation of services, and the dynamic interplay among key market regions provide a detailed roadmap for industry advancement. The narrative outlined earlier reinforces that strategic agility, through innovative process development and regulatory alignment, is the cornerstone for remaining competitive. As the field continues to mature, organizations that adopt a forward-thinking approach will be best positioned to embrace new opportunities and overcome emerging challenges.

The collective insights presented in this review illuminate how meticulous segmentation and regional analysis are critical in mapping out growth strategies. Equally, the actions of leading companies offer invaluable benchmarks and best practices that can be replicated for enhanced production efficiency and market penetration. By uniting scientific innovation with strategic planning, the path forward becomes clearer, offering a promise of groundbreaking therapies that meet the urgent demands of healthcare across the globe. The consolidated message is one of resilience and proactive adaptation - qualities that are essential for transforming challenges into opportunities in an ever-changing regulatory and technological landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases and genetic disorders
      • 5.1.1.2. Increase in government funding and grants for research and development of advanced therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High operational costs associated with cell & gene therapy manufacturing
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising adoption of CRISPR technology providing a new growth trajectory in genetic engineering services
      • 5.1.3.2. Technological advancements in bioprocessing equipment create avenues for efficient production processes
    • 5.1.4. Challenges
      • 5.1.4.1. Quality control and contamination issues in cell & gene therapy production
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Service Type: Need for cell banking services for providing secure storage and access to various cell lines
    • 5.2.2. Technology Type: Proliferating usage of the viral vectors for their high transfection efficiency and stable gene expression
    • 5.2.3. Therapeutic Area: Significance of cell gene therapy in oncology for treating hematological malignancies and solid tumors
    • 5.2.4. Application: Utilization of clinical manufacturing to enable preclinical testing and clinical trials
    • 5.2.5. End-User: Rising adoption across pharmaceutical & biotech companies for the development and commercialization of innovative therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Manufacturing Services Market, by Service Type

  • 6.1. Introduction
  • 6.2. Analytical & Quality Control Services
  • 6.3. Cell Banking Services
  • 6.4. Consulting Services
  • 6.5. Fill & Finish Services
  • 6.6. GMP Manufacturing Services
  • 6.7. Process Development Services
  • 6.8. Regulatory Support Services
  • 6.9. Supply Chain & Logistics Services
  • 6.10. Technology Transfer Services
  • 6.11. Vector Production Services

7. Cell & Gene Therapy Manufacturing Services Market, by Technology Type

  • 7.1. Introduction
  • 7.2. Gene Editing
    • 7.2.1. CRISPR/Cas9
    • 7.2.2. Transcription Activator-Like Effector Nucleases
    • 7.2.3. Zinc Finger Nucleases
  • 7.3. Vectors
    • 7.3.1. Non-Viral Vectors
      • 7.3.1.1. Cationic Lipids
      • 7.3.1.2. Chitosan-Based Vectors
      • 7.3.1.3. Dendrimers
      • 7.3.1.4. Inorganic Nanoparticles
      • 7.3.1.5. Liposomes
      • 7.3.1.6. Naked DNA/RNA
      • 7.3.1.7. Peptide-Based Vectors
      • 7.3.1.8. Polymeric Vectors
    • 7.3.2. Viral Vectors
      • 7.3.2.1. Adeno-Associated Virus (AAV) Vectors
      • 7.3.2.2. Adenovirus Vectors
      • 7.3.2.3. Herpes Simplex Virus (HSV) Vectors
      • 7.3.2.4. Retrovirus Vectors

8. Cell & Gene Therapy Manufacturing Services Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
    • 8.2.1. Coronary Artery Disease
    • 8.2.2. Heart Failure
  • 8.3. Infectious Diseases
    • 8.3.1. Hepatitis B
    • 8.3.2. HIV
  • 8.4. Monogenic Disorders
    • 8.4.1. Cystic Fibrosis
    • 8.4.2. Hemophilia
    • 8.4.3. Sickle Cell Anemia
  • 8.5. Oncology
    • 8.5.1. Hematological Malignancies
    • 8.5.2. Solid Tumors

9. Cell & Gene Therapy Manufacturing Services Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Manufacturing
  • 9.3. Commercial Manufacturing

10. Cell & Gene Therapy Manufacturing Services Market, by End-User

  • 10.1. Introduction
  • 10.2. Contract Research Organizations
  • 10.3. Hospitals & Clinics
  • 10.4. Pharmaceutical & Biotech Companies
  • 10.5. Research Institutes & Academic Institutions

11. Americas Cell & Gene Therapy Manufacturing Services Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cell & Gene Therapy Manufacturing Services Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. OmniaBio revolutionizes cell & gene therapy manufacturing with AI-driven facility in Ontario,
    • 14.3.2. eXmoor Pharma and Virica Biotech are collaborating to enhance the manufacturing efficiency of adeno-associated vectors
    • 14.3.3. Strategic collaboration between SK pharmteco and Cryoport revolutionizes cell & gene therapy logistics and manufacturing
    • 14.3.4. eXmoor Pharma's MIA(IMP) license fuels expansion in GMP-grade cell & gene therapy manufacturing
    • 14.3.5. Cryoport and Minaris unite to revolutionize cell & gene therapy with integrated services
    • 14.3.6. Merck KGaA's acquisition of Mirus Bio enhances viral vector manufacturing for cell & gene therapies
    • 14.3.7. ProPharma and PBL collaborate on innovative cell & gene therapy manufacturing
    • 14.3.8. Memel Biotech revolutionizes cell & gene therapy manufacturing with new Klaipeda facility launch
    • 14.3.9. FUJIFILM invests USD 200 million to increase cell therapy CDMO capabilities amid market surge
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Charles River Laboratories International, Inc.
    • 14.4.2. Lonza Group AG
    • 14.4.3. Takara Bio Inc.
    • 14.4.4. Merck KGaA

Companies Mentioned

  • 1. Advanced BioScience Laboratories, Inc. by Institut Merieux
  • 2. AGC Biologics
  • 3. AmplifyBio
  • 4. Bio-Techne Corporation
  • 5. C.H. Boehringer Sohn AG & Co. KG
  • 6. Catalent, Inc.
  • 7. Cell Therapies Pty Ltd.
  • 8. Cell-Easy
  • 9. Charles River Laboratories International, Inc.
  • 10. Danaher Corporation
  • 11. eXmoor Pharma Concepts Limited
  • 12. FUJIFILM Diosynth Biotechnologies
  • 13. Genezen Laboratories, Inc.
  • 14. Laboratory Corporation of America Holdings
  • 15. Lonza Group AG
  • 16. Merck KGaA
  • 17. Miltenyi Biotec B.V. & Co. KG
  • 18. Minaris Regenerative Medicine GmbH by Resonac Corporation
  • 19. Nikon Corporation
  • 20. Novartis AG
  • 21. Oxford Biomedica PLC
  • 22. ProPharma Group Holdings, LLC
  • 23. Recipharm AB
  • 24. Samsung Biologics Co., Ltd.
  • 25. SGS S.A.
  • 26. STEMCELL Technologies Inc.
  • 27. Takara Bio Inc.
  • 28. Thermo Fisher Scientific Inc.
  • 29. uBriGene Biosciences Inc.
  • 30. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET MULTI-CURRENCY
  • FIGURE 2. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET MULTI-LANGUAGE
  • FIGURE 3. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH PROCESS
  • FIGURE 4. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 100. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 101. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 102. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 111. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 112. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 113. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 114. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 116. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 117. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 118. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 124. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 125. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 126. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 127. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 128. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 129. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 130. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 131. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 162. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 166. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 168. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 170. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 172. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 178. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 179. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 180. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 181. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 183. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 184. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 185. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 191. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 192. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 193. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 194. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 195. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 196. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 197. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 198. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 204. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 205. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 206. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 207. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 208. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 209. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 210. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 211. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 217. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 218. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 219. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 220. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 221. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 222. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 223. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 224. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 230. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 231. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 232. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 233. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 234. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 235. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 236. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 237. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 243. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 244. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 245. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 246. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 247. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 248. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 249. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 250. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 256. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 257. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 258. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 259. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 260. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 261. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 262. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 263. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 266. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 269. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 270. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 271. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 272. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC